Comtan

RSS

entacapone

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine.

If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 26/10/2021

Authorisation details

Product details
Name
Comtan
Agency product number
EMEA/H/C/000171
Active substance
entacapone
International non-proprietary name (INN) or common name
entacapone
Therapeutic area (MeSH)
Parkinson Disease
Anatomical therapeutic chemical (ATC) code
N04BX02
Publication details
Marketing-authorisation holder
Orion Corporation
Revision
26
Date of issue of marketing authorisation valid throughout the European Union
22/09/1998
Contact address

Orionintie 1
FIN-02200 Espoo
Finland

Product information

11/10/2021 Comtan - EMEA/H/C/000171 - N/0058

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Anti-Parkinson drugs

Therapeutic indication

Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.

Assessment history

How useful was this page?

Add your rating
Average
4 ratings
1 rating
1 rating